Abbott’s FreeStyle Libre System, which was approved by the U.S. Food and Drug Administration in September and launched in U.S. pharmacies in November, has met the criteria for therapeutic continuous glucose monitoring used for coverage by the U.S. Centers for Medicare and Medicaid Service, Abbott said.
Although I do not yet see a confirmation statement directly from Medicare. Which of course would be interesting. Particularly as it was the Medicare “fine print” in regards to the Dexcom coverage which continues to cause significant displeasure.
Hmmm… Wondering if Abbott is getting tricky with wording.
"… met the criteria …"
Actually is not QUITE the same as Medicare PROVIDING coverage.
Something smells just a little bit stinky here…